Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event?
Fibrosis is the end point of most renal diseases, and several glycosaminoglycans have been shown to attenuate this process. Marine invertebrate glycosaminoglycans with unique structures have opened the possibility to test these new compounds on renal fibrosis. The effect of a fucosylated chondroitin sulfate from an echinoderm marine species is reported with the use of a model of renal fibrosis in rats, termed unilateral ureteral obstruction. Animals were given 4 mg/kg body wt of fucosylated chondroitin sulfate intraperitoneally, once a day. After 14 days, their kidneys were examined by histological, immunohistochemical, and biochemical methods. Compared with control mice, collagen deposition decreased in the course of renal fibrosis in the animals receiving fucosylated chondroitin sulfate, as revealed by Sirius red staining and hydroxyproline content. The cellularity related to myofibroblasts and macrophages was also reduced, as was the production of transforming growth factor (TGF)-β. The glycosaminoglycan content increased in the renal interstitium of animals submitted to unilateral ureteral obstruction compared with the control contralateral kidney, mostly due to an increase of chondroitin sulfate content. Interestingly, no change in the pattern of glycosaminoglycan deposition was observed after administration of fucosylated chondroitin sulfate. Fibrosis induced by unilateral ureteral obstruction is attenuated in P-selectin-deficient mice, which also do not respond to the invertebrate glycosaminoglycan. In conclusion, fucosylated chondroitin sulfate attenuates renal fibrosis on a ureteral obstruction model in mice preponderantly through a P-selectin-mediated mechanism.
Melo-Filho
Nelson M
NM
Laboratório de Tecido Conjuntivo, Instituto de Bioquímica Médica, and Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil.
Belmiro
Celso L
CL
Gonçalves
Rômulo G
RG
Takiya
Christina M
CM
Leite
Maurilo
M
Pavão
Mauro S G
MS
Mourão
Paulo A S
PA
D000818:Animals; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003094:Collagen / Q000378:metabolism; D005355:Fibrosis / Q000517:prevention & control; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000378:metabolism; D008297:Male; D051379:Mice; D058628:Myofibroblasts / Q000378:metabolism; D019007:P-Selectin / Q000502:physiology*; D051381:Rats; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014517:Ureteral Obstruction / Q000378:metabolism / Q000473:pathology*
D019007:P-Selectin; D016212:Transforming Growth Factor beta; C517150:fucosylated chondroitin sulfate; D002809:Chondroitin Sulfates; D003094:Collagen